Based on this evidence, a possible explanation for the difference observed in the EudraVigilance data in the sex distribution of oncologic SARs to IL‐23 inhibitors can be supported by the pre‐existing higher prevalence of cancer in male patients with psoriasis. This evidence concerns the gene IL23A and psoriasis.